158 related articles for article (PubMed ID: 33368138)
1. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Koike C; Okudela K; Matsumura M; Mitsui H; Suzuki T; Arai H; Kataoka T; Ishikawa Y; Umeda S; Tateishi Y; Ohashi K
Histol Histopathol; 2021 Mar; 36(3):305-315. PubMed ID: 33368138
[TBL] [Abstract][Full Text] [Related]
2. A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.
Matsumura M; Okudela K; Kojima Y; Umeda S; Tateishi Y; Sekine A; Arai H; Woo T; Tajiri M; Ohashi K
PLoS One; 2016; 11(11):e0166795. PubMed ID: 27861549
[TBL] [Abstract][Full Text] [Related]
3. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
5. Associations of
Chang JH; Lai TC; Yang PJ; Shih PC; Yang YC; Lee KL; Liu TC; Tsao TC; Yang SF; Chien MH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126605
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
Goto E; Taki T; Nomura K; Miyakami Y; Miyoshi T; Tane K; Samejima J; Aokage K; Nagamine M; Sakashita S; Sakamoto N; Kojima M; Suzuki K; Tsuboi M; Ishii G
Lung Cancer; 2024 Jun; 192():107830. PubMed ID: 38805901
[TBL] [Abstract][Full Text] [Related]
7. The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases.
Okudela K; Matsumura M; Arai H; Woo T
Cancer Sci; 2021 Sep; 112(9):3411-3418. PubMed ID: 34143937
[TBL] [Abstract][Full Text] [Related]
8. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
9. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
12. Differences in Immunological Landscape between
Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
[TBL] [Abstract][Full Text] [Related]
14. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Miller CT; Aggarwal S; Lin TK; Dagenais SL; Contreras JI; Orringer MB; Glover TW; Beer DG; Lin L
Cancer Res; 2003 Jul; 63(14):4136-43. PubMed ID: 12874018
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
[TBL] [Abstract][Full Text] [Related]
17. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
[TBL] [Abstract][Full Text] [Related]
18. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
Soma S; Tsuta K; Takano T; Hatanaka Y; Yoshida A; Suzuki K; Asamura H; Tsuda H
Pathol Res Pract; 2014 Mar; 210(3):155-60. PubMed ID: 24355440
[TBL] [Abstract][Full Text] [Related]
20. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
